Chester County drug developer Virpax working on ‘molecular mask’ to combat Covid-19
By John George – Senior Reporter, Philadelphia Business Journal Virpax Pharmaceuticals Inc. has joined the battle against Covid-19 through a new technology licensing agreement with a London life sciences company. The Chester County drug developer signed the deal with Nanomerics Ltd. for the exclusive North America rights to [...]
Virpax Enters into an NIH Collaboration to Further Develop NES100 for Acute and Chronic Non-Cancer Pain
Announces CRADA with National Center for Advancing Translational Sciences Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that it has entered into a cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), an institute/center of the [...]
Virpax Enters into License Agreement to Develop High-Density Molecular Masking Spray Formulation (MMS019) for the Prevention of Respiratory Viruses
Nasal Powder Spray May Provide Barrier for Cell Transmission of Respiratory Infections Virpax Pharmaceuticals Inc. (“Virpax”), today announced the signing of a technology license agreement with Nanomerics Ltd. (“Nanomerics”) for the exclusive North America rights to use Nanomerics’ High-Density Molecular Masking Spray (MMS019) for the prevention of seasonal influenza [...]
Virpax Pharmaceuticals Announces Appointment of Christopher M. Chipman, Chief Financial Officer
Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products that incorporate the use of novel drug delivery systems for pain management, today announced the appointment of Christopher M. Chipman, CPA, Chief Financial Officer. “As Chairman of the Audit Committee, it is with great pleasure that I welcome Chris [...]
Virpax Pharmaceuticals Strengthens Board of Directors with Appointment of Gary S. Jacob, Ph.D. to its Board
Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products that incorporate the use of novel drug delivery systems for pain management, today announced the appointment of Gary S. Jacob, Ph.D. to its Board of Directors.“We are pleased to welcome Dr. Jacob as a new independent director to [...]
Virpax Pharmaceuticals Announces Successful Completion of Pre-IND Meeting with FDA on Epoladerm for the Management of Osteoarthritis of the Knee
505(b)(2) Regulatory Pathway and Proposed Study Design Is Acceptable Virpax to Finalize IND and Prepare for Phase I Human Study Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, today announced that it has successfully completed a [...]
Virpax Pharmaceuticals Announces Successful Completion of Pre-IND Meeting with FDA on NES100 for the Management of Acute and Chronic Pain
Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems today announced that it has successfully completed a pre-Investigational New Drug (IND) Application meeting with the U.S. Food and Drug Administration (FDA) for NES100 which uses the Nanomerics [...]
Virpax Pharmaceuticals Selected for Two Presentations at the 2020 Special Operations Medical Association Exhibition
Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that their Chief Medical Officer Jeffrey Gudin, M.D., will present two abstracts at the 2020 Special Operations Medical Association’s Training, Education, Scientific Assembly and Exhibition (SOMA) being held May 11-15, 2020, at the [...]
Virpax to Develop Its Molecular Envelope Technology (MET) Intranasal Enkephalin Formulation for the Management of PTSD
Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, signed a technology license agreement with Nanomerics Ltd. Under the agreement, Virpax has exclusive global rights to use Nanomerics’ nanotechnology for the delivery of a metabolically labile intranasal [...]
Gerald Bruce Joins Virpax Pharmaceuticals as Executive Vice President, Commercial Operations
Virpax Pharmaceuticals Inc. (“Virpax”) a company specializing in developing pharmaceutical products for pain management, today announced that Gerald W. Bruce, has joined Virpax as Executive Vice President, Commercial Operations. Mr. Bruce most recently served as Vice President of Sales for Specialized Nutrition at Danone North America. “We are pleased [...]
Virpax Pharmaceuticals Announces the Appointment of Three Independent Directors
Virpax Pharmaceuticals Inc. (“Virpax”) a company specializing in developing pharmaceutical products for pain management, is pleased to announce the appointment of three independent directors: Eric Floyd, PhD, Jerrold Sendrow, CFP and Thani Jambulingam, PhD, at their Annual General Meeting of the Shareholders held on Monday, September 9, 2019 [...]
Virpax Pharmaceuticals to Present at the 2019 Military Health System Research Symposium
Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that their Chief Medical Officer Jeffrey Gudin, M.D., will present two posters at the 2019 Military Health System Research Symposium (MHSRS) being held August 19-22, 2019, at the Gaylord Palms Resort and [...]
Virpax Pharmaceuticals Selected for Two Presentations at the 2019 Military Health System Research Symposium
Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that their Chief Medical Officer Jeffrey Gudin, M.D., will present two abstracts at the 2019 Military Health System Research Symposium (MHSRS) being held August 19-22, 2019, at the Gaylord Palms Resort and [...]
Virpax Pharmaceuticals to Present at ThinkEquity Conference
Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, today announced that Anthony P. Mack, Chairman and CEO of Virpax will be presenting at the ThinkEquity Conference at 12:30 p.m. ET on Thursday, May 2, 2019 in [...]
Virpax Pharmaceuticals Licenses Molecular Envelope Technology (MET) Intranasal Formulation From Nanomerics Ltd.
Virpax to Develop a Non-Opioid Molecular Envelope Technology (MET) Intranasal Formulation for the Management of Chronic Pain Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, signed a technology license agreement with Nanomerics Ltd. Under the agreement, [...]
Virpax Pharmaceuticals Announces Successful Pre-IND Meeting for LBL100
505(b)(2) Regulatory Pathway and Proposed Study Design Is Acceptable Virpax to Finalize IND and Prepare for Phase 1 Human Study Virpax Pharmaceuticals ("Virpax"), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, completed a successful pre-Investigational New Drug ("pre-IND") Meeting with [...]
[FEATURED] Is Biopharma Still Committed To Its Role In Public Health?
This article from Life Science Leader magazine features the views of top executives, including Virpax's CEO Anthony Mack, on how the life sciences industry business model meets public health obligations. Read more on lifescienceleader.com
Virpax Pharmaceuticals Reports Pre-IND Guidance From FDA for DSF100
505(b)(2) Regulatory Pathway and Proposed Study Design Is Acceptable Virpax to Finalize IND and Prepare for Phase 1 Human Study Virpax Pharmaceuticals (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, received a written response from the US Food and [...]